← back to search

C. Frank Bennett

Pennsylvania State University · US
Area of research
Molecular Biology · Genetics
Research interest
Research interests include Neurogenetic and Muscular Disorders Research, RNA Interference and Gene Delivery, RNA Research and Splicing, and DNA and Nucleic Acid Chemistry.
h-index
100
citations
47,058
works
326
NIH funding
primary concept
Biology
email

Recent publications

Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy
Science Translational Medicine 2025cited by 16position: middledoi
A splice-switching antisense oligonucleotide approach for pediatric genetic epilepsies
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 1position: middledoi
Mechanism of <i>STMN2</i> cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies
Science 2023cited by 241position: middledoi
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
The Lancet Neurology 2023cited by 52position: lastdoi
Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation
Nature Neuroscience 2023cited by 48position: middledoi
Personalized antisense oligonucleotides ‘for free, for life’ — the n-Lorem Foundation
Nature Medicine 2023cited by 32position: middledoi
Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTB
Nature Neuroscience 2021cited by 67position: middledoi
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
New England Journal of Medicine 2020cited by 533position: middledoi
Antisense Drugs Make Sense for Neurological Diseases
The Annual Review of Pharmacology and Toxicology 2020cited by 109position: firstdoi
High-resolution visualization and quantification of nucleic acid–based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS)
Nucleic Acids Research 2020cited by 70position: middledoi
ALS-associated genes in SCA2 mouse spinal cord transcriptomes
Human Molecular Genetics 2020cited by 29position: middledoi
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration
Nature Neuroscience 2019cited by 657position: middledoi
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Annual Review of Neuroscience 2019cited by 340position: firstdoi
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Journal of Clinical Investigation 2019cited by 189position: middledoi
Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
Muscle & Nerve 2019cited by 88position: middledoi
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
New England Journal of Medicine 2018cited by 1,412position: middledoi
RNA-Targeted Therapeutics
Cell Metabolism 2018cited by 788position: middledoi
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Journal of Clinical Investigation 2018cited by 267position: middledoi
Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells
Molecular Therapy 2018cited by 87position: middledoi
Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7
Science Translational Medicine 2018cited by 84position: middledoi
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Nature 2017cited by 326position: middledoi
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
The Lancet 2016cited by 1,010position: middledoi
Results from a phase 1 study of nusinersen (ISIS-SMN <sub>Rx</sub> ) in children with spinal muscular atrophy
Neurology 2016cited by 598position: middledoi
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs
Neuron 2016cited by 537position: middledoi
Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System
Neuron 2016cited by 191position: middledoi
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy
Neuron 2016cited by 137position: middledoi
Modulation of LMNA splicing as a strategy to treat prelamin A diseases
Journal of Clinical Investigation 2016cited by 106position: middledoi
Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal Metabolism
Cell Metabolism 2016cited by 96position: middledoi
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release
Parkinsonism & Related Disorders 2015cited by 50position: middledoi
Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy
Cell Reports 2014cited by 175position: middledoi

Grants

ADVANCE Partnership: Supporting Public Impact Research through Institutional Transformation (SPIRIT)
NSF2404600$1,249,9992024–2028PIRePORTER
Conference: A Three-Part Series to Envision & Enact an Inclusive & Diverse STEM Professoriate
NSF2041007$99,8742020–2022PIRePORTER
Collaborative Research: NSF INCLUDES Alliance: National Alliance for Inclusive and Diverse STEM Faculty (NAIDSF)
NSF1834518$5,758,7642018–2025PIRePORTER
The geochemical ecology of cryptoendolithic microorganisms: relationships between cyanobacteria and sandstone weathering in the Canadian High Arctic
NSF0909482$355,9362009–2013PIRePORTER
Collaborative Research: Biogeochemical Controls on Antimony and Arsenic Mobility in a Siliceous Hydrothermal System
NSF0545336$129,9562006–2009PIRePORTER
The Kinetics of Microbial Sulfuric Acid Speleogenesis
NSF0617160$67,8212006–2010PIRePORTER
Optimized Variable Stiffness Energy Returning Ankle Foot Orthosis
NSF0503256$299,8252005–2008PIRePORTER
Sediment Transport in an Urbanizing Karst Aquifer-Watershed
NSF0001197$90,0002001–2004PIRePORTER
LExEn: Sulfuric Acid Speleogenesis by Chemolithotrophic Bacteria: Community Structure and Habitat Modification by Acid Extremophiles
NSF0085576$341,2152000–2004PIRePORTER
Microbial Weathering of Silicates: Aggressive Release of Limiting Nutrients
NSF9903267$144,0001999–2002PIRePORTER
Mass Transport Properties of Fracture Skins
NSF9316465$246,6091994–1998PIRePORTER
ARFMP: Replacement of Chemistry Research and Research Training Laboratories
NSF9021741$816,0001991–1992PIRePORTER
Silicate Dissolution in Organic-Rich Aqueous Systems: Reaction Mechanisms and Rate Controls
NSF9105778$129,3001991–1994PIRePORTER
NSF Postdoctoral Fellowship in Plant Biology
NSF8312553$79,6181983–1987PIRePORTER
Research Initiation: Interaction of Large-Scale Motion WithA Secondary Contraction (Mechanical Engineering and Applied Mechanics)
NSF8205051$47,9851982–1983PIRePORTER

Frequent collaborators

Frank Rigo · Ionis Pharmaceuticals (United States)11 papers (2013–2023)Don W. Cleveland · University of California San Diego10 papers (2012–2023)Kathie M. Bishop · Acadia Pharmaceuticals (United States)6 papers (2013–2023)Gene Hung · Ionis Pharmaceuticals (United States)6 papers (2012–2018)Jacqueline Montes · Columbia University Irving Medical Center4 papers (2016–2019)Michael W. Baughn · University of California San Diego4 papers (2012–2023)Darryl C. De Vivo · Columbia University Irving Medical Center4 papers (2016–2019)Clotilde Lagier‐Tourenne · Massachusetts General Hospital4 papers (2012–2023)John Ravits · University of California System3 papers (2012–2019)Richard S. Finkel · Veterans Affairs Canada3 papers (2016–2019)Eugene Schneider · Ionis Pharmaceuticals (United States)3 papers (2016–2019)Claudia A. Chiriboga · Columbia University Irving Medical Center3 papers (2016–2018)Karen Ling · Ionis Pharmaceuticals (United States)3 papers (2016–2023)Holly Kordasiewicz · Ionis Pharmaceuticals (United States)3 papers (2012–2020)Albert R. La Spada · University of California, Irvine3 papers (2014–2018)Basil T. Darras · Boston Children's Hospital3 papers (2016–2019)Bryce L. Sopher · Seattle University2 papers (2014–2018)Stephen G. Young · Institute of Human Genetics2 papers (2016–2020)Charlotte J. Sumner · Johns Hopkins University2 papers (2016–2025)Daniel M. Ramos · Bial (Portugal)2 papers (2016–2019)